H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cognition Therapeutics (CGTX – Research Report) today and set a price target of $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight the potential of Cognition Therapeutics. The company has successfully secured a philanthropic donation to fund an expanded access program for zervimesine, a promising treatment for dementia with Lewy bodies. This non-dilutive funding demonstrates the company’s ability to manage operational costs effectively, which is a positive indicator for investors.
Additionally, Cognition Therapeutics is making progress in its regulatory pathway, with plans for end-of-Phase 2 meetings with the FDA to discuss future clinical protocols for both Alzheimer’s disease and dementia with Lewy bodies. The anticipated regulatory clarity and continued access to non-dilutive funding sources are expected to support the development of zervimesine, reinforcing the Buy rating with a 12-month price target of $3.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 16.5% and a 48.28% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Anavex Life Sciences, and Axsome Therapeutics.